Spontaneous reporting is still one of the most important ways to detect new drug safety problems. Yet most suspected adverse drug reactions are never reported. A widely cited systematic review by Hazell and Shakir (2006) estimated a median under-reporting rate of around 94% across the studies it examined.
That gap matters. A safety signal that needs ten reports to stand out may take years to appear if only a fraction of cases reach the system. In this article I look at why under-reporting happens and what pharmacists, and the companies that train them, can do about it.
Why healthcare professionals don't report
Research going back to the 1970s has identified recurring attitudes behind under-reporting (Lopez-Gonzalez et al., 2009). They are still recognisable today:
- Complacency: the belief that only safe medicines reach the market.
- Uncertainty: not reporting because it is unclear whether the drug really caused the reaction.
- Indifference: the feeling that one report will not make a difference.
- Lack of time: reporting competes with every other task in a busy shift.
- Lack of knowledge: not knowing what to report, how, or to whom.
- Fear or guilt: worry about liability, or about having contributed to the harm.
In my experience in Swiss community pharmacies, uncertainty and time are the most common barriers. Many professionals think they must be sure before reporting. In fact, a reasonable suspicion is enough.
Why pharmacists are well placed
Pharmacists see patients more often than most other healthcare professionals (van Grootheest & de Jong-van den Berg, 2005). Patients come back for repeat prescriptions, ask for advice on self-medication and describe symptoms they might not mention to their doctor.
Pharmacists also see the full medication picture. A pharmacy record shows prescriptions from several doctors, plus over-the-counter products bought in the same pharmacy. That makes interactions and duplications easier to spot.
Finally, pharmacists are often the first to hear about reactions to non-prescription medicines and herbal products. These are rarely reported through other routes (van Grootheest & de Jong-van den Berg, 2005).
Practical steps that work
From my work at Amavita and Coop Vitality, these habits make the biggest difference.
- Make the question routine. When dispensing a repeat prescription, asking "How are you getting on with this medicine?" opens the door to reports that would otherwise be missed.
- Document immediately. Notes made during the conversation capture dates and details that disappear by the end of the day.
- Lower the threshold. Reporting a suspicion, not a certainty, is what the system needs. Clear team guidance on what counts as reportable removes hesitation.
- Share cases within the team. Discussing a reported case helps colleagues recognise similar presentations. It also turns reporting into a normal part of practice rather than an exception.
- Support new colleagues. Showing someone how to complete their first report removes the uncertainty that stops many people from starting.
Training is the lever companies can pull
Under-reporting is not only a problem for authorities. Pharmaceutical companies receive safety information through many channels: sales and medical representatives, patient support programmes, market research, customer service and social media.
Every one of these employees and partners must recognise an adverse event and forward it to the safety team within a short timeframe. That is why companies run regular adverse event reporting training for staff and business partners (European Medicines Agency [EMA], 2017).
Good training has the same features as good pharmacy practice:
- it uses real-sounding examples instead of abstract definitions;
- it explains that a suspicion is enough;
- it gives one simple route for forwarding information;
- it explains why the timelines matter, not just what they are.
What under-reporting means for data interpretation
Under-reporting also affects how safety data are read. Spontaneous reports cannot be used to calculate how often a reaction occurs, because the true number of cases and the number of exposed patients are unknown (Hazell & Shakir, 2006).
Reporting can also rise for reasons unrelated to risk, such as media attention or a safety communication (Pariente et al., 2007). Safety scientists therefore treat spontaneous data as a signal-detection tool and confirm signals with other sources, such as clinical trials, observational studies and the literature (Council for International Organizations of Medical Sciences [CIOMS], 2010).
Why this matters to employers
A safety function is only as good as the information that reaches it. People who understand how reports are generated in real healthcare settings can design better training, ask better follow-up questions and interpret spontaneous data more carefully.
My years in hospital and community pharmacy, combined with drug safety training during my MSc, have given me that practical understanding.
Key takeaways
- Most suspected ADRs are never reported; the gap delays signal detection.
- Uncertainty and lack of time are major barriers; a suspicion is enough to report.
- Clear, example-based training is the most effective way to improve reporting.
References
Council for International Organizations of Medical Sciences. (2010). Practical aspects of signal detection in pharmacovigilance: Report of CIOMS Working Group VIII. CIOMS.
European Medicines Agency. (2017). Guideline on good pharmacovigilance practices (GVP): Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). https://www.ema.europa.eu
Hazell, L., & Shakir, S. A. W. (2006). Under-reporting of adverse drug reactions: A systematic review. Drug Safety, 29(5), 385–396. https://doi.org/10.2165/00002018-200629050-00003
Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2009). Determinants of under-reporting of adverse drug reactions: A systematic review. Drug Safety, 32(1), 19–31. https://doi.org/10.2165/00002018-200932010-00002
Pariente, A., Gregoire, F., Fourrier-Reglat, A., Haramburu, F., & Moore, N. (2007). Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias. Drug Safety, 30(10), 891–898.
van Grootheest, K., & de Jong-van den Berg, L. (2005). The role of hospital and community pharmacists in pharmacovigilance. Research in Social and Administrative Pharmacy, 1(1), 126–133.
Member discussion